PROphylaxis in NOn Major Orthopaedic Surgery (PRONOMOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02401594|
Recruitment Status : Terminated (Remaining outdated treatments and additional costs too high for new manufacturing)
First Posted : March 30, 2015
Last Update Posted : December 7, 2018
PRONOMOS is an international multicentre, interventional, parallel, randomised, double-blind non-inferiority study comparing rivaroxaban 10mg od to an active comparator, enoxaparin 4000 UI od in 4040 valid subjects requiring orthopaedic surgery (except low risk such material removal foot surgery or hallux valgus without patient risk factor , and major orthopaedic surgeries for femoral neck and trochanteric fractures, THR, TKR)
Pre-randomization treatment with LMWH anticoagulant is allowed for a maximum duration of 24 hours. However, only a single pre-randomization dose of LMWH is allowed. After randomization, patients allocated to the rivaroxaban arm will receive rivaroxaban 10 mg once-daily started 6-10 hours provided haemostasis has been established after surgery or 24h hours after LMWH injection if needed for the intended treatment duration of 2 to 12 weeks based on medical judgment (according to immobilization). Patients allocated to the comparator arm will receive enoxaparin once daily for the same intended treatment duration. All patients will have a 30-day observational period after cessation of treatment.
|Condition or disease||Intervention/treatment||Phase|
|Non-major Orthopaedic Surgery||Drug: Rivaroxaban Drug: Enoxaparin||Phase 3|
Major orthopedic surgery (hip, knee replacements and hip fracture) represents only a small part of all orthopaedic surgery procedures. Procedures for trauma patients and orthopaedic lower limb surgery without trauma are much more frequent (tibia osteotomy, arthrodesis, ligament repair….).
The incidence of trauma patients requiring surgery and prolonged immobilisation is rising, mainly because of the increasing popularity of recreational sports. However, the epidemiology and prevention of VTE after such injuries have been poorly studied. The combination of limb surgery with or without trauma in orthopaedic surgery is responsible for an increase in venous thromboembolism (VTE). Usually, surgery of lower limb is considered as moderate or high risk for DVT with different duration related to immobilisation. For instance tibia osteotomy is at very high risk during at least 6 weeks and knee arthroscopy for ligament repair is at moderate risk during 10 days. However LMWH is recommended in both surgeries. Non-major orthopaedic surgery represents a major additional risk factor by itself; therefore such patients undergoing surgery deserve to receive VTE prophylaxis.
Rivaroxaban is a new oral anticoagulant developing a potent anti-Xa activity. In major orthopaedic surgery, it has shown to be more effective and as safe as LMWH (Enoxaparin 4000 IU once daily) in THR and TKR patients (RECORD program). Up to now, pending the limited number of surgical settings in which it has been developed in orthopaedic surgery, it is only approved for the prevention of venous thromboembolism (VTE) in THR and TKR procedures, which represent only 20% of all orthopaedic interventions. Non-major elective lower limb surgery and traumatology population is younger as compared to prosthetic orthopaedic surgery patients. Fewer VTE and cardiovascular events are to be feared. These patients receive quite often injectable thromboprophylaxis for a total duration lying between approximately 6 weeks to 3 months. In the one hand, the risk of major bleeding is low in this younger population. On the other hand, compliance and cost should be in favour of Rivaroxaban, because no injection and no platelets counts are needed.
The results of Xamos descriptive sub-analysis in non-elective (fracture related) orthopaedic surgery are consistent with the overall results of Xamos and are in favour of further investigations in this area. In this small subset of patients (n=790), the incidence of symptomatic thromboembolic events observed was low in patients treated with Xarelto and the overall frequency of treatment emergent major bleedings was low in both groups and serious adverse events occurred less frequently in patients treated with Xarelto. Therefore, collection of clinical data in this population is needed and awaited by many orthopaedic surgeons and anaesthetists in charge of VTE prophylaxis.
The population with femoral neck and trochanteric fracture is a specific one with different characteristics, elderly, frail and with a higher bleeding risk. This population will be excluded.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3608 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery|
|Actual Study Start Date :||December 8, 2015|
|Actual Primary Completion Date :||April 11, 2018|
|Actual Study Completion Date :||April 16, 2018|
Experimental: Group 1: Rivaroxaban treatment
Rivaroxaban active substance plus a placebo of enoxaparin
10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
Other Name: Group 1:
Active Comparator: Grouyp 2: Enoxaparine treatment
Enoxaparin active substance plus a placebo tablet of Rivaroxaban
A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
Other Name: Group 2:
- Major VTE [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum). ]
composite of proximal DVT (asymptomatic and symptomatic) assessed by ultrasonography, symptomatic events (distal and proximal DVT, PE) and VTE related deaths.
The treatment period ranges from 15 days to 3 months depending on the type of surgery
- Major bleeding [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum). ]
bleeding event that meets at least one of the following criteria :
- fatal bleeding;
- critical bleeding (intracranial, intraocular, intraspinal, pericardial, retroperitoneal);
- clinically overt bleeding (at surgical or extrasurgical site) associated with a decrease in the haemoglobin level of more than 2 g/dL (20 g/l; 1.24 mmol/L) compared with the pre-randomization level;
- clinically overt bleeding (at surgical or extrasurgical site) leading to transfusion of two or more units of whole blood or packed cells;
- bleeding located at the surgical site and leading to re-operation or to any unusual medical intervention or procedure for relief (e.g. draining or puncture of an haematoma at the surgical site, transfer to an ICU or emergency room) The treatment period ranges from 15 days to 3 months depending on the type of surgery
- Clinically relevant non-major bleeding [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum).. ]
overt bleeding not meeting the criteria for major bleeding and corresponds to any bleeding necessitating medical intervention or a specific, unscheduled consultation or treatment discontinuation, or resulting in a deterioration of the subject's quality of life. Some examples of clinically significant bleeding are given below:
- Epistaxis that lasts more than five minutes or recurrent or necessitates packing,
- Spontaneous macroscopic haematuria or haematuria lasting more than 24 hours after instrumentation,
- Gastrointestinal haemorrhage (melena or rectorrhagia),
- Subcutaneous haematoma > 100 cm². The treatment period ranges from 15 days to 3 months depending on the type of surgery
- Overt thrombocytopenia [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum).. ]platelet count <100 giga/L or fall ≥ 50% of the platelet count as compared with the first post-operative count which will be done as local lab for all centres The treatment period ranges from 15 days to 3 months depending on the type of surgery
- Mortality [ Time Frame: From date of randomization until the date of the end of the treatment period (up to 3 months maximum).. ]All cause mortality The treatment period ranges from 15 days to 3 months depending on the type of surgery
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02401594
|Study Director:||Marc SAMAMA, PhD||Assistance Publique - Hôpitaux de Paris|
|Study Director:||Nadia ROSENCHER, MD||Assistance Publique - Hôpitaux de Paris|
|Principal Investigator:||Patrick MISMETTI, PhD||Centre Hospitalier Universitaire de Saint Etienne|